Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.21
BSPM's Cash-to-Debt is ranked lower than
84% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. BSPM: 0.21 )
Ranked among companies with meaningful Cash-to-Debt only.
BSPM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 27.05 Max: No Debt
Current: 0.21
Equity-to-Asset 0.87
BSPM's Equity-to-Asset is ranked higher than
86% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. BSPM: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
BSPM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79  Med: 0.87 Max: 0.96
Current: 0.87
0.79
0.96
Piotroski F-Score: 4
Altman Z-Score: 0.15
Beneish M-Score: -1.35
WACC vs ROIC
10.02%
-16.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -164.99
BSPM's Operating Margin % is ranked lower than
89% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. BSPM: -164.99 )
Ranked among companies with meaningful Operating Margin % only.
BSPM' s Operating Margin % Range Over the Past 10 Years
Min: -164.99  Med: 10.36 Max: 30.5
Current: -164.99
-164.99
30.5
Net Margin % -255.43
BSPM's Net Margin % is ranked lower than
90% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. BSPM: -255.43 )
Ranked among companies with meaningful Net Margin % only.
BSPM' s Net Margin % Range Over the Past 10 Years
Min: -255.43  Med: 10.57 Max: 24.95
Current: -255.43
-255.43
24.95
ROE % -16.31
BSPM's ROE % is ranked lower than
78% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. BSPM: -16.31 )
Ranked among companies with meaningful ROE % only.
BSPM' s ROE % Range Over the Past 10 Years
Min: -43.08  Med: 12.48 Max: 34.28
Current: -16.31
-43.08
34.28
ROA % -14.04
BSPM's ROA % is ranked lower than
79% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. BSPM: -14.04 )
Ranked among companies with meaningful ROA % only.
BSPM' s ROA % Range Over the Past 10 Years
Min: -37.87  Med: 11.32 Max: 30.2
Current: -14.04
-37.87
30.2
ROC (Joel Greenblatt) % -28.30
BSPM's ROC (Joel Greenblatt) % is ranked lower than
77% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. BSPM: -28.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSPM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -74.36  Med: 29.36 Max: 96.91
Current: -28.3
-74.36
96.91
3-Year Revenue Growth Rate -68.10
BSPM's 3-Year Revenue Growth Rate is ranked lower than
97% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. BSPM: -68.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSPM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.1  Med: -19.4 Max: 56.5
Current: -68.1
-68.1
56.5
GuruFocus has detected 6 Warning Signs with Biostar Pharmaceuticals Inc $BSPM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSPM's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB, AMEX:CPHI, NAS:ALQA, NAS:NVGN, OTCPK:INNV, AMEX:AXN, OTCPK:SUWN, NAS:IMNP, OTCPK:CHEXD, NAS:TNXP, NAS:PRPH, NAS:OASM, NAS:ALIM, AMEX:NNVC, OTCPK:CKDXF, NAS:NBRV, NAS:ZGNX, OTCPK:ABSCF » details
Traded in other countries:7BNB.Germany,
Headquarter Location:China
Biostar Pharmaceuticals Inc, through its subsidiaries is engaged in the business of developing, manufacturing and marketing over-the-counter and prescription pharmaceutical products in the Peoples Republic of China.

Biostar Pharmaceuticals Inc is a Maryland corporation incorporated on March 27, 2007. It is a holding company that through its wholly-owned subsidiary Shaanxi Biostar Biotech, Ltd. and its variable interest entities Shaanxi Aoxing Pharmaceutical Co., Ltd., and Shaanxi Weinan Aoxing Pharmaceuticals, LLC develops, manufactures and markets pharmaceutical products for a variety of diseases and conditions in the Peoples Republic of China. Its popular product is Xin Ao Xing Oleanolic Acid Capsule, an over-the- counter (OTC) medicine for chronic hepatitis B. Its product line also includes five other OTC products, ten prescription-based pharmaceuticals, six nutriceuticals or health products and one medical device. The Company's products are derived from medicinal herbs that are either grown at its own facility or purchased from its suppliers. It has currently eight products under development to complement its existing product line. It has adopted international manufacturing standards and currently holds one patent, with two additional patents pending approval. The Company's products are currently being sold in over 25 provinces in the PRC through 25 distributors and an established network of more than 400 dedicated sales people. The Company's competitors includes, Wulanhaote Zhong Meng pharmaceutical Co., Ltd., Yang Ling Mai Di Sen Pharmaceutical Co., Ltd, Jiang Xi Ren He Pharmaceuticals, Inc; Hainan Asia Pharmaceuticals, Inc; Nan Yong An Pharmaceuticals, Inc; Hai Nan Min Hai Pharmaceuticals, Ltd; Shandong Bai Cao Pharmaceuticals, Ltd; Chang Chun Ren Min Pharmaceuticals, Ltd; Yun Nan Yu Xi City Wei He Pharmaceutical, Ltd; Shandong Phoenix Pharmaceuticals, Ltd; Wulanhaote Zhong Meng Pharmaceutical Co., Ltd; Yang Ling Mai Di Sen Pharmaceutical Co., Ltd; and other traditional Chinese medicine suppliers. The Company' operations and facilities are subject to environmental laws and regulations stipulated by the national and the local environment protection bureaus in the PRC.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 3.26
BSPM's Price-to-Owner-Earnings is ranked higher than
97% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. BSPM: 3.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSPM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.69  Med: 4.68 Max: 392.26
Current: 3.26
0.69
392.26
PB Ratio 0.10
BSPM's PB Ratio is ranked higher than
100% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. BSPM: 0.10 )
Ranked among companies with meaningful PB Ratio only.
BSPM' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.26 Max: 3.22
Current: 0.1
0.06
3.22
PS Ratio 2.07
BSPM's PS Ratio is ranked higher than
60% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. BSPM: 2.07 )
Ranked among companies with meaningful PS Ratio only.
BSPM' s PS Ratio Range Over the Past 10 Years
Min: 0.13  Med: 0.36 Max: 3.51
Current: 2.07
0.13
3.51
Price-to-Free-Cash-Flow 0.74
BSPM's Price-to-Free-Cash-Flow is ranked higher than
99% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. BSPM: 0.74 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSPM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.5  Med: 3.06 Max: 70
Current: 0.74
0.5
70
Price-to-Operating-Cash-Flow 0.74
BSPM's Price-to-Operating-Cash-Flow is ranked higher than
99% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. BSPM: 0.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSPM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.5  Med: 2.77 Max: 1793.75
Current: 0.74
0.5
1793.75
Current Ratio 1.19
BSPM's Current Ratio is ranked lower than
83% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. BSPM: 1.19 )
Ranked among companies with meaningful Current Ratio only.
BSPM' s Current Ratio Range Over the Past 10 Years
Min: 1.12  Med: 4.9 Max: 19.49
Current: 1.19
1.12
19.49
Quick Ratio 1.16
BSPM's Quick Ratio is ranked lower than
70% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. BSPM: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
BSPM' s Quick Ratio Range Over the Past 10 Years
Min: 1.05  Med: 4.82 Max: 19.17
Current: 1.16
1.05
19.17
Days Inventory 68.63
BSPM's Days Inventory is ranked higher than
76% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. BSPM: 68.63 )
Ranked among companies with meaningful Days Inventory only.
BSPM' s Days Inventory Range Over the Past 10 Years
Min: 6.29  Med: 10.84 Max: 68.63
Current: 68.63
6.29
68.63
Days Sales Outstanding 850.29
BSPM's Days Sales Outstanding is ranked lower than
100% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. BSPM: 850.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSPM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 94.72  Med: 137.3 Max: 1032.07
Current: 850.29
94.72
1032.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.40
BSPM's 3-Year Average Share Buyback Ratio is ranked lower than
77% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. BSPM: -13.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSPM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.1  Med: -11.7 Max: -8.5
Current: -13.4
-18.1
-8.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 3.69
BSPM's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 521 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.35 vs. BSPM: 3.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BSPM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.25  Med: 0.67 Max: 10.94
Current: 3.69
0.25
10.94
Price-to-Tangible-Book 0.12
BSPM's Price-to-Tangible-Book is ranked higher than
100% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. BSPM: 0.12 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BSPM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.11  Med: 0.32 Max: 3.48
Current: 0.12
0.11
3.48
Price-to-Intrinsic-Value-Projected-FCF 0.06
BSPM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. BSPM: 0.06 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSPM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.28
Current: 0.06
0.05
0.28
Price-to-Median-PS-Value 5.76
BSPM's Price-to-Median-PS-Value is ranked lower than
97% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. BSPM: 5.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSPM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 1 Max: 9.24
Current: 5.76
0.38
9.24
Earnings Yield (Greenblatt) % -55.53
BSPM's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. BSPM: -55.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSPM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -33602.6  Med: 12.3 Max: 973548.4
Current: -55.53
-33602.6
973548.4

More Statistics

Revenue (TTM) (Mil) $2.39
EPS (TTM) $ -2.60
Beta1.12
Short Percentage of Float13.61%
52-Week Range $1.20 - 7.06
Shares Outstanding (Mil)2.66
» More Articles for BSPM

Headlines

Articles On GuruFocus.com
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 
GMO Global Equity Insights - Whiplash: On Value, Growth and Ignoring the Fundamentals Jun 26 2017 
Dan Loeb's Third Point Letter on $3.5 Billion Nestle Purchase, Plans to Sells L'Oreal Jun 26 2017 
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 
A Look at Darden Valuation Jun 26 2017 
Is Dollar Tree Oversold With Potential Cuts to SNAP? Jun 26 2017 

More From Other Websites
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended March 31, 2017 May 19 2017
Biostar Pharmaceuticals, Inc. Announces Its Annual Results for The Year Ended December 31, 2016 Apr 13 2017
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended September 30,... Nov 21 2016
Biostar Pharmaceuticals Completes Previously Announced Registered Direct Financing Oct 18 2016
Biostar Announces Execution of Agreement for $1.91 Million Registered Direct Offering of Shares of... Oct 12 2016
Biostar to Launch a New Product Aimed at Treating Effects of Rhinitis and Sinusitis Oct 11 2016
Biostar Pharmaceuticals Signs a Letter of Intent to Acquire Xianyang Yongsheng Health Products Co.,... Sep 22 2016
Biostar Pharmaceuticals, Inc. Announces Its Quarterly Results for Three Months Ended June 30, 2016 Aug 22 2016
BioStar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BSPM) : November 3, 2015 Nov 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}